摘要
目的评价马来酸桂哌齐特治疗肾绞痛的临床疗效及安全性。方法将76例肾绞痛患者随机分成对照组36例和试验组40例。对照组予以肌内注射氯诺昔康8 mg+黄体酮40 mg,qd;试验组在对照组的基础上,加用静脉滴注马来酸桂哌齐特320 mg+10%葡萄糖注射液500 m L,糖尿病患者改为0.9%氯化钠500 m L,qd。观察患者6 h内疼痛缓解程度、是否复发和不良反应发生率。结果试验组有效率和显效率分别为100.00%和92.50%显著高于对照组88.89%和69.40%(P<0.05)。6 h内试验组肾绞痛再发率为0显著低于对照组再发率13.89%(P<0.05)。2组均未见明显的药物相关性不良反应。结论马来酸桂哌齐特能够明显缓解肾绞痛,降低再发率,且无明显不良反应,值得临床推荐。
Objective To observe the clinical therapeutic effect of cine- pazide maleate in the treatment of renal colic. Methods Seventy - six patients of renal colic were randomly divided into 2 groups. The control group（36 patients） received lornoxicam 8 mg and progesterone 40 mg by intramuscular injection qd. The treatment group （40 patients） received cinepazide maleate 320 mg by intravenous drip qd additionally. The de- gree of pain relief, recurrence and incidence of adverse reactions were observed in 6 h. Results The efficiency and significant efficiency of the treatment group were 100.00% and 92.50%. In contrast, the efficiency and significant efficiency of the control group were 88.89% and 69.44% respectively and the differences were statistically significant. Within 6 hours of treatment, treatment group recurrent rate of renal colic （0） , was lower than that of control group （13.89%）. The two groups were no obvious adverse reaction of drug associated. Conclusion Cinepazide maleate could obviously relieve renal colic, reduce the recurrence rate, and not lead to significant adverse reactions. So, cinepazide maleate is a new choice for the treatment of renal colic.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2015年第18期1822-1824,共3页
The Chinese Journal of Clinical Pharmacology
基金
广州医科大学校级科研基金资助项目(2013A29)
关键词
肾绞痛
马来酸桂哌齐特
腺苷
氧自由基
解痉
renal colic
cinepazide maleate
adenosine
oxygen free radicals
spasmolysis
